PRCT as reported
PROCEPT BioRobotics Corporation reported $322M of revenue over the trailing twelve months, +29% on the year before. 10 reported series are charted on this page, each one as filed.
$322M
Revenue, trailing twelve months · to Q1 2026 · +29% against the twelve months before
- Net Income
- −$102M
Net Income · +14% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$81M
Free Cash Flow · −8.7% year on year · trailing twelve months to Q1 2026
- Op Margin
- −34%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $322M | +29% | Q1 2026 |
| Net Income | −$102M | +14% | Q1 2026 |
| EPS | −$1.82 | +7.7% | Q1 2026 |
| Gross Margin | 64% | n/a | Q1 2026 |
| Op Margin | −34% | n/a | Q1 2026 |
| Net Margin | −32% | n/a | Q1 2026 |
| ROE | −25% | n/a | Q1 2026 |
| ROA | −18% | n/a | Q1 2026 |
| ROIC | −56% | n/a | Q1 2026 |
| Free Cash Flow | −$81M | −8.7% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
PROCEPT BioRobotics Corporation (PRCT) - Revenue & ProfitRevenue & ProfitPROCEPT BioRobotics Corporation (PRCT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com